This clinical imaging study will use the small molecule translocator protein (TSPO) ligand, Fluorodeoxyglucose(18F)-labeled DPA-714, to visualize and quantify neuroinflammation in individuals with post-acute sequelae of SARS-CoV-2 (PASC) . The brain uptake of DPA-714 will be contrasted with healthy subjects.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
60
DPA-714 PET/MRI
UAB
Birmingham, Alabama, United States
RECRUITINGMeasurement of regional brain TSPO levels using PET in participants with neurological PASC and healthy volunteers
PET measures of TSPO binding in brain regions including cerebral cortex, thalami, and brainstem will be quantified in symptomatic study participants and healthy volunteers will be collected and compared between groups
Time frame: Injection/scan date to clinical follow-up. (Usually within 6 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.